Entera Bio Ltd. (ENTX)

Market Closed

12 Jun, 20:00

NASDAQ (CM)

1. 23

+0.07

+6.0345%

Pre Market

1. 28

+0.05 +4.065%

60.13M Market Cap

- P/E Ratio

- Div Yield

45,824 Volume

-0.32 Eps

$ 1.16

Previous Close

Investors:

HFT

Add Transaction

Day Range

1.15 1.23

Year Range

0.91 3.22

Want to track ENTX and more in your Portfolio? 🎯

Get Started For Free

Summary

ENTX closed Friday higher at $1.23, an increase of 6.0345% from Thursday's close, completing a monthly increase of 6.9565% or $0.08. Over the past 12 months, ENTX stock lost -37.2449%.

ENTX is not paying dividends to its shareholders.

The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0.15%. On average, the company has surpassed earnings expectations by 0.1167%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

ENTX Chart

People also search for

BNTC

Benitec Biopharma Inc.

$ 11.18

+1.1765%

PALI

Palisade Bio Inc.

$ 1.71

-3.9326%

NVCT

Nuvectis Pharma Inc.

$ 10.71

+1.9029%

CMPX

Compass Therapeutics Inc.

$ 2.03

+0.995%

ELTX

Elicio Therapeutics Inc.

$ 14.85

+6.528%

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 month ago

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

Seekingalpha | 1 month ago

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates

Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.

Zacks | 1 year ago

Entera Bio Ltd. Investors

Name	Quantity	Cost	Value	Profit ($)	Gain (%)
Point72 Asset Management LP Point72 Asset Management LP	12,382	$24,021.08	$15,229.86	-$8,791.22	-36.6%
HFT Hui Fai Tam Caitong International Asset Management Co. Ltd.	20	$22	$24.6	$2.6	11.82%
Zachary Canonico DIADEMA PARTNERS LP	23,260	$25,819	$28,609.8	$2,790.8	10.81%

ENTX Investors

Entera Bio Ltd. (ENTX) FAQ

What is the stock price today?

The current price is $1.23.

On which exchange is it traded?

Entera Bio Ltd. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is ENTX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 60.13M.

Has Entera Bio Ltd. ever had a stock split?

No, there has never been a stock split.

Entera Bio Ltd. Profile

Biotechnology Industry	Healthcare Sector	Miranda J. Toledano CEO	NASDAQ (CM) Exchange	M40527109 CUSIP
IL Country	18 Employees	- Last Dividend	- Last Split	28 Jun 2018 IPO Date

Overview

Entera Bio Ltd. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of orally delivered peptide and protein therapeutics for addressing unmet medical needs. The company leverages its expertise to advance a pipeline of proprietary programs in various stages of clinical development. Established in 2009 and headquartered in Jerusalem, Israel, Entera Bio has established a research collaboration and license agreement with Amgen Inc., aiming at the discovery and development of clinical candidates targeting inflammatory diseases and other serious illnesses. This collaboration underscores Entera Bio's commitment to leveraging partnerships to accelerate its drug development efforts.

Products and Services

EB612

EB612 is a pioneering candidate positioned in Phase II clinical trials, specifically designed for the treatment of hypoparathyroidism. This condition, characterized by abnormally low levels of parathyroid hormone, often leads to calcium imbalance. By focusing on this candidate, Entera Bio is addressing a significant unmet medical need with the potential to offer a new oral therapy option.

EB613

This candidate has completed Phase II clinical trials aimed at treating osteoporosis, a condition that weakens bones, making them fragile and more likely to break. Additionally, EB613 is in Phase I clinical trials for the treatment of non-union fractures, which are breaks that fail to heal on their own. Entera Bio's development of EB613 showcases its commitment to innovative treatments for bone health.

GLP-2

GLP-2, another key product candidate, is in early-stage preclinical trials for the treatment of short bowel syndrome (SBS). SBS is a disorder that typically occurs due to the surgical removal of a large portion of the intestine, leading to malabsorption. Entera Bio's work on GLP-2 demonstrates its effort to explore treatments for complex gastrointestinal conditions.

hGh (Human Growth Hormone)

Targeted at addressing growth hormone (GH) deficiency, hGh is under development by Entera Bio. GH deficiency can lead to a range of health issues, affecting both children and adults. By working on an oral formulation of hGh, Entera Bio aims to improve the quality of life for patients suffering from this deficiency, highlighting its broad focus on endocrine disorders.

Contact Information

Address: Kiryat Hadassah Minrav Building

Phone: 972 2 532 7151

Website: https://www.enterabio.com

Blog Affiliate Program About Terms Privacy Help Contact Us